Study
Responsiveness of epigenetic aging biomarkers to longevity interventions in humans
The TransLAGE analysis harmonized 51 human intervention studies and found the strongest clock responses in mortality- and pace-of-aging-trained measures, with explainable clocks offering more mechanistic detail.
Summary Which aging tests best detect whether a human intervention is working? Show / hide ↓
Researchers combined 51 human intervention studies and applied 16 epigenetic clocks, tests that use chemical tags on DNA to estimate biological aging. They also examined 94 DNA-methylation biomarkers, individual DNA tags linked to health processes, to help explain the results. The studies included lifestyle and drug interventions, but the total number of participants was not reported on the available page. Clocks trained to predict death risk or the pace of aging changed most consistently, and drug and lifestyle interventions produced the strongest DNA changes. Results varied with the people studied and how long the intervention lasted.
What this means for you: This does not show that a particular supplement or drug extends life, so it is not a reason to buy one. It may help future trials choose better aging tests, but clock results alone are not proof of better health or longer life.
moderate evidenceRaghav Sehgal and colleagues built TransLAGE, a harmonized database covering 51 public and private longitudinal intervention studies. They calculated 16 prominent epigenetic clocks for each study and added 94 DNA-methylation biomarkers to help interpret clock changes. Clocks trained on mortality risk or pace of aging showed the strongest and most consistent responses across interventions. Pharmacological and lifestyle interventions produced the strongest DNA-methylation responses. Study population and intervention duration affected responsiveness. The analysis also favors explainable clocks with multiple subscores over single-score clocks because the subscores can identify biological processes that move in opposite directions. The work is a methods and evidence-synthesis contribution, not a new randomized trial of one molecule. The fetched PubMed page does not state the participant total, pooled effect sizes, confidence intervals, or p values. It therefore cannot show that any specific supplement or drug extends life. Its immediate value is practical. Trial designers can select clocks and biomarker subsets before recruitment, reduce multiple testing, and avoid treating every change in an epigenetic clock as equivalent. The findings also support caution: clock choice, population, and duration can decide whether an intervention appears biologically active.
Moreover, clocks with multiple subscores (that is 'explainable clocks') provide specificity and greater mechanistic insight into the responsiveness of interventions than single-score clocks. These findings can help to design future clinical trials by guiding the choice of interventions and of specific subsets of DNAm biomarkers to minimize multiple testing, study duration, study population and sample size, with the eventual aim of uncovering DNAm biomarkers that can be used as surrogate aging endpoints.
The abstract describes a database of 51 studies but does not state the total participant count or pooled effect sizes in the fetched record. Clock responsiveness is not the same as proven clinical benefit. Many interventions and populations are combined, so the analysis should guide trial design rather than rank supplements by efficacy.
Cited by
1 encyclopedia entries reference this study.